Efficacy of onabotulinumtoxinA treatment in episodic migraine

BackgroundOnabotulinumtoxinA (BoNT-A) is approved as a prophylactic treatment of chronic migraine (CM) only. We aimed to assess the efficacy and safety of BoNT-A in the treatment of episodic migraine (EM).MethodsThis is a prospective study included migraine patients, aged 18–65 years, and completed...

Full description

Saved in:
Bibliographic Details
Main Authors: Jasem Al-Hashel, Raed Alroughani, Malak Almojel, Samar Farouk Ahmed
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1459767/full
Tags: Add Tag
No Tags, Be the first to tag this record!